Cardiovascular Disease Patients
Developing innovative therapy for
heart and cardiovascular disease
Vericel’s mission is to help cardiovascular disease patients realize the promise of a patient-specific, expanded multicellular therapy called ixmyelocel-T.By starting with the patient’s own bone marrow, which is accepted by the patient’s immune system, we believe we can eliminate both the risk of rejection and that of having to use immunosuppressive therapy pre- or post-therapy.
Clinical trials for heart disease treatment
Vericel is currently conducting clinical trials for dilated cardiomyopahy (DCM).
Dilated Cardiomyopathy: Dilated cardiomyopathy (DCM) is the most common form of heart failure. We are administering a clinical trial for dilated cardiomyopathy, currently recruiting in Phase 2b. Learn more about DCM clinical trials.